Ex vivo pembrolizumab pharmacology for personalized PD-1 inhibitor therapy reveals a critical gap between receptor occupancy and T cell functionality
We highlight the importance of evaluating T cell functionality alongside PD-1 receptor occupancy. We identified PD-1-induced modulation of phosphorylation of proximal signalling molecules as potential predictors for ICI treatment response in NSCLC. We recommend further development of this immunopharmacological bioassay for personalization of ICI treatment.
Authors
- Rob ter Heine (ORCID: https://orcid.org/0000-0003-2185-8201)
- Hans J. P. M. Koenen (ORCID: https://orcid.org/0000-0003-1210-7502)
- Michel M. van den Heuvel (ORCID: https://orcid.org/0000-0002-6372-2153)
- Berber Piet (ORCID: https://orcid.org/0000-0002-9069-3597)
- Ruben L. Smeets (ORCID: https://orcid.org/0000-0002-2862-1058)
- Judith D J Verdonk
Institutions
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
- Radboud Institute for Molecular Life Sciences (NL)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1016/j.intimp.2025.114754
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14